Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data-Reference-Cited by-同舟云学术

Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data

Published:2017-12-12 Issue:26 Volume:1 Page:2637-2642
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Rota Matteo¹^ORCID,Cortesi Paolo A.¹²^ORCID,Crea Roberto³,Gringeri Alessandro³,Mantovani Lorenzo G.¹^ORCID

Affiliation:

1. Research Centre on Public Health, University of Milan-Bicocca, Monza, Italy;

2. Fondazione Charta, Milan, Italy; and

3. Shire, Vienna, Austria

Abstract

Key Points AICC has been used since 1977 to control bleeding in patients with hemophilia with inhibitors. AICC is associated with a low incidence of TEEs, especially when administered prophylactically.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/1/26/2637/879989/advances011536.pdf

Reference50 articles.

1. How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors;Leissinger;Blood,2015

2. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study;Astermark;Blood,2007

3. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity;Aledort;J Thromb Haemost,2004

4. Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(®) in prophylactic therapy;Varadi;Haemophilia,2016

5. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison;Young;Haemophilia,2008

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A szerzett haemophilia A gyors diagnosztikája ClotPro viszkoelasztometriás készülékkel;Orvosi Hetilap;2023-10-08

2. Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA Global Outcome (FEIBA GO) study;Therapeutic Advances in Hematology;2023-01

3. Is there any place for replacement therapy of hemophilia A in children in present and future?;Russian Journal of Pediatric Hematology and Oncology;2022-11-09

4. Engineered Molecular Therapeutics Targeting Fibrin and the Coagulation System: a Biophysical Perspective;Biophysical Reviews;2022-04

5. Current Therapeutic Approach to Acute Myocardial Infarction in Patients with Congenital Hemophilia;Life;2021-10-11